309 related articles for article (PubMed ID: 9307267)
1. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
[TBL] [Abstract][Full Text] [Related]
2. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC
J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897
[TBL] [Abstract][Full Text] [Related]
3. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Chen ZP; Wang G; Huang Q; Sun ZF; Zhou LY; Wang AD; Panasci LC
J Neurooncol; 1999 Aug; 44(1):7-14. PubMed ID: 10582663
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Chen ZP; Pan J; Huang Q; Sun ZF; Zhou LY; Wang AD
J Neurooncol; 2001 Jan; 51(1):19-24. PubMed ID: 11349876
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
Skalski V; Yarosh DB; Batist G; Gros P; Feindel W; Kopriva D; Panasci LC
Mol Pharmacol; 1990 Sep; 38(3):299-305. PubMed ID: 2402223
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study.
Kitamura I; Kochi M; Matsumoto Y; Ueoka R; Kuratsu J; Ushio Y
Cancer Res; 1996 Sep; 56(17):3986-92. PubMed ID: 8752168
[TBL] [Abstract][Full Text] [Related]
8. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
[TBL] [Abstract][Full Text] [Related]
9. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Dolan ME; Fleig MJ; Feuerstein BG; Basu HS; Luk GD; Casero RA; Marton LJ
Cancer Res; 1994 Sep; 54(17):4698-702. PubMed ID: 8062267
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
Skalski V; Rivas J; Panasci L; McQuillan A; Feindel W
Cancer Chemother Pharmacol; 1988; 22(2):137-40. PubMed ID: 3409444
[TBL] [Abstract][Full Text] [Related]
11. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Huynh H; Nguyen TH; Panasci L; Do P
Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
14. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
Noë AJ; Malapetsa A; Panasci LC
Cancer Res; 1994 Mar; 54(6):1491-6. PubMed ID: 8137253
[TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
17. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Emerich DF; Winn SR; Bartus RT
Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219
[TBL] [Abstract][Full Text] [Related]
18. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
Noë AJ; Malapetsa A; Panasci LC
Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272
[TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Slagel DE; Feola J; Houchens DP; Ovejera AA
Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.
Schold SC; Friedman HS; Bjornsson TD; Bigner DD
Cancer Res; 1984 Jun; 44(6):2352-7. PubMed ID: 6722774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
